This year we have a great story to kick-off European Narcolepsy Day!
Narcolepsy UK have facilitated a meeting to initiate the creation of a European Patient Advisory Group to work closely with pharmaceutical companies on research and clinical trials of new medicines for Narcolepsy.
Even collectively, we would struggle to fund research but this way, we hope that we can provide our knowledge and assistance to make things happen faster.
Flamel (Part of the Avadel Pharmaceuticals), are looking for subjects to participate in their clinical trial evaluating their once nightly sodium oxybate for the treatment of EDS and cataplexy in narcolepsy.
FT218 is dosed once at bedtime unlike the currently marketed formulation of sodium oxybate (Xyrem®) which needs to be taken twice nightly, once at bedtime and then again 2.5 – 4 hours later.
Patients with a diagnosis of narcolepsy who meet the study criteria may be eligible to participate in our clinical trial.